Please login to the form below

Not currently logged in


This page shows the latest patritumab news and features for those working in and with pharma, biotech and healthcare.

Daiichi starts challenging Astellas for Japanese AML market

Daiichi has suffered a clutch of cancer setbacks in recent years, including the 2014 failure of an anti-EGFR asset and the 2016 wipeout of patritumab.

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...